Τίτλος:
Genotyping KRAS and EGFR mutations in Greek patients with non-small-cell lung cancer: Incidence, significance and implications for treatment
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Background/Aim: KRAS mutations are reported in 20-25% of non-small cell lung cancer (NSCLC) and their prognostic role is unclear. We studied KRAS and EGFR genotyping in Greek NSCLC patients. Patients and Methods: KRAS and EGFR genotypes were centrally evaluated in 421 NSCLC patients (diagnosed September 1998 -June 2013) and associated with clinicopathological parameters. Outcome comparisons were performed in 288 patients receiving first line treatment. Results: Most patients were male (78.6%), >60 years old (63.9%), current smokers (51.1%), with adenocarcinoma histology (63.9%). EGFR and KRAS mutations were found in 10.7% and 16.6% of all histologies, respectively, and in 14.9% and 21.9% of adenocarcinomas. At 4.5 years median follow-up, KRAS status was an independent negative prognostic factor for overall survival (OS, p=0.016). KRAS mutations conferred 80% increased risk of death in patients receiving first-line treatment (p=0.002). Conclusion: The presence of KRAS mutations is an independent negative prognosticator among Greek NSCLC patients and an independent response predictor to first line treatment. © 2019 International Institute of Anticancer Research. All rights reserved.
Συγγραφείς:
Linardou, H.
Kotoula, V.
Kouvatseas, G.
Mountzios, G.
Karavasilis, V.
Samantas, E.
Kalogera-Fountzila, A.
Televantou, D.
Papadopoulou, K.
Mavropoulou, X.
Daskalaki, E.
Zaramboukas, T.
Efstratiou, I.
Lampaki, S.
Rallis, G.
Res, E.
Syrigos, K.N.
Kosmidis, P.A.
Pectasides, D.
Fountzilas, G.
Περιοδικό:
Cancer Genomics and Proteomics
Εκδότης:
International Institute of Anticancer Research
Λέξεις-κλειδιά:
epidermal growth factor receptor; K ras protein; EGFR protein, human; epidermal growth factor receptor; KRAS protein, human; protein p21, adult; aged; Article; cancer incidence; cancer therapy; controlled study; current smoker; female; follow up; gene mutation; genotype; Greece; human; human tissue; lung adenocarcinoma; major clinical study; male; non small cell lung cancer; overall survival; retrospective study; clinical trial; disease free survival; genetics; genotyping technique; lung tumor; middle aged; mortality; mutation; non small cell lung cancer; survival rate; very elderly, Adult; Aged; Aged, 80 and over; Carcinoma, Non-Small-Cell Lung; Disease-Free Survival; ErbB Receptors; Female; Follow-Up Studies; Genotyping Techniques; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Proto-Oncogene Proteins p21(ras); Retrospective Studies; Survival Rate
